I would for a couple of reasons.  While this is an active area of research without large scale phase 3 trials to prove it, I do think that the adoption of neoadjuvant therapy for pancreas cancer makes a lot of sense. We know even from older data that preoperative RT reduces the risk of margin ...

PREOPANC trial did not prove benefits, as per recent final report. I think it maybe useful in special borderline resectable situations...

The use of chemoradiation in resectable pancreatic cancer should not be considered routine standard of care, but can be used strategically in borderline resectable tumors and tumors in which additional "space" is needed.  While neoadjuvant therapy in pancreatic cancer is becoming more routine a...

Local radiotherapy has never added to survival in localized pancreatic cancer and is not without toxicities. Why with a more effective regimen would it be expected to add now